Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life.

COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government's Healthy China 2030 public health plan.

Dupixent is now approved in four indications across respiratory and dermatological diseases in China.